COVID-19 and atopic dermatitis
The coronavirus disease 2019 (COVID-19) has become a pandemic and a global public health emergency. At the moment, we do not yet know why some people get sicker than others. We also do not know if people with atopic dermatitis (AD) are affected differently, due to their disease or because of the medication they are taking.
Atopic dermatitis and COVID-19 registries
AD, also known as eczema, is a common chronic inflammatory skin disease. In people with moderate-to-severe AD, medications can be used that influence the immune system; either in the form of tablets or injections (systemic medication). The impact of these systemic medications on COVID-19 outcomes is currently unknown. That is why we have set up two international COVID-registries for AD: one that is completed by health care providers and one that is completed by patients themselves. It is called: SECURE-AD.
How do these registries work?
When you have AD and you have been diagnosed with COVID-19 or when COVID-19 is strongly suspected, even if this was a while back, we encourage you to complete the patient survey of the SECURE-AD Patients Registry, so that we can understand your personal experience of the infection. Please also let your doctor know about your infection episode and ask them to enter your case in the SECURE-AD Physician Registry. Both online registries complement each other, are safe and secure, collect anonymised data and have received the relevant ethical/Institutional Review Board approvals.
By collecting worldwide data on COVID-19 and AD, SECURE-AD will make it possible to assess the impact of COVID-19 on AD patients and what influence AD treatments have on the course of the infection. This will help to guide doctors in their care of AD patients who are infected with COVID-19. In addition, SECURE-AD works closely together with similar COVID-19 registries, such as for psoriasis, alopecia areata, rheumatic diseases and inflammatory bowel diseases, so that we can compare our results and experiences. This makes the impact of the SECURE-AD project even greater. In a joint effort we can address the uncertainties we currently face.
Please visit our website or check the frequently asked questions. If you want to report your case, you can go directly to the patient survey page. Your support is very much appreciated!
The SECURE-AD Steering Group & International Scientific Advisory Committee
The post COVID-19 and atopic dermatitis appeared first on Eczema Association of Australasia Inc.